Preview

Атеротромбоз

Расширенный поиск

АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА КАК ПРОФИЛАКТИЧЕСКОЕ АНТИТРОМБОТИЧЕСКОЕ СРЕДСТВО. НАЧАЛО КОНЦА БЕСКОНЕЧНОЙ ИСТОРИИ?

https://doi.org/10.21518/2307-1109-2013-1-73-81

Полный текст:

Аннотация

.

Об авторе

О. В. Аверков
Городская клиническая больница №15 им. О.М. Филатова и РУДН, Москва
Россия


Список литературы

1. Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients//BMJ. 1994. № 308. Р. 81–106.

2. US Preventive Services Task Force: Aspirin for the prevention of cardiovascular disease: U. S. Preventive Services Task Force recommendation statement// Ann. Intern. Med. 2009. № 150. Р. 396–404. Medline.

3. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U. S. Preventive Services Task Force//Ann. Intern. Med. 2009. № 150. Р. 405–410.

4. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)//Eur. Heart. J. 2012, Jul. № 33 (13). Р. 1635–701.

5. American Diabetes Association. Standards of Medical Care in Diabetes–2013//Diabetes Care. 2013. № 36. S. 11–S. 66.

6. Camm A. J., Lip G. Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation//Eur. Heart. J. 2012. № 33. Р. 2719–2747.

7. Jones C. G., Cleland J. G. Meeting report: the LIDO, HOPE, MOXCON and WASH studies: Heart Outcomes Prevention Evaluation. TheWarfarin/ Aspirin Study of Heart Failure//Eur. J. Heart. Fail. 1999. № 1 (4). Р. 425–431.

8. Massie B. Final results of the warfarin and antiplatelet trial in chronic heart failure (WATCH): a randomized comparison of warfarin, aspirin and clopidogrel//J. Card. Fail. 2004. № 10 (2). Р. 101–112.

9. Dewilde W. Jm., Oirbans T. Verheugt FWA, for the WOEST study investigators//Lancet 2013. DOI: 10.1016/S0140–6736 (12)62177–1.

10. Connolly S. J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation//The New Engl. J. Med. 2011. № 364 (9). Р. 806–817.

11. Sacco R. L., Diener H. C., Yusuf S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke//N. Engl. J. Med. 2008. № 359. Р. 1238.

12. Verro P., Gorelick P. B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a metaanalysis// Stroke. 2008. № 39 Р. 1358.

13. Eikelboom J. W., Mehta S. R., Anand S. S., Xie C., Fox K. A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes//Circulation. 2006. № 114. Р. 774–782.

14. Budaj A., Eikelboom J. W., Mehta S. R., et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes//Eur. Heart. J. 2009. № 30. Р. 655–661.

15. Mehran R., Pocock S. J., Stone G. W., etal. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial//Eur. Heart. J. 2009. № 30. Р. 1457–1466.

16. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M. C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials//Lancet. 2009. № 373. Р. 1849–1860.

17. McQuaid K. R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials// Am. J. Med. 2006. № 119. Р. 624–638.

18. De Berardis G., Sacco M., Strippoli G. F., Pellegrini F., Graziano G., Tognoni G., Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials//BMJ. 2009. № 339. b4531 Abstract.

19. Zhang C., Sun A., Zhang P., Wu C., Zhang S., Fu M., Wang K., Zou Y., Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis//Diabetes Res. Clin. Pract. 2010. № 87. Р. 211–218.

20. Calvin A. D., Aggarwal N. R., Murad M. H., Shi Q., Elamin M. B., Geske J. B., Fernandez-Balsells M. M., Albuquerque F. N., Lampropulos J. F., Erwin P. J., Smith S. A., Montori V. M. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes//Diabetes Care. 2009. № 32. Р. 2300–2306.

21. Catalano M., Born G., Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial//J. Intern. Med. 2007. № 261. Р. 276–284.

22. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease//BMJ. 2008. № 337. a1840.

23. Fowkes F. G., Price J. F., Stewart M. C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial//JAMA. 2010. № 303. Р. 841–848.

24. Berger J. S., Krantz M. J., Kittelson J. M., et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials//JAMA. 2009. № 301. Р. 1909–1919.

25. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)// Lancet. 1996. № 348. Р. 1329–1339.


Для цитирования:


Аверков О.В. АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА КАК ПРОФИЛАКТИЧЕСКОЕ АНТИТРОМБОТИЧЕСКОЕ СРЕДСТВО. НАЧАЛО КОНЦА БЕСКОНЕЧНОЙ ИСТОРИИ? Атеротромбоз. 2013;(1):73-81. https://doi.org/10.21518/2307-1109-2013-1-73-81

For citation:


Аверков О.В. Atherothrombosis. 2013;(1):73-81. (In Russ.) https://doi.org/10.21518/2307-1109-2013-1-73-81

Просмотров: 358


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)